Group A rotavirus universal mass vaccination: how and to what extent will selective pressure influence prevalence of rotavirus genotypes?

Jelle Matthijnssens Laboratory of Clinical and Epidemiological Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium;

Osamu Nakagomi Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, and Global Center of Excellence, Nagasaki University, Nagasaki, Japan; Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, and Global Center of Excellence, Nagasaki University, Nagasaki, Japan

Carl D Kirkwood Enteric Virus Group, Murdoch Childrens Research Institute, Royal Children’s Hospital, Parkville, and Department of Microbiology, La Trobe University, Bundoora, Victoria, Australia; Enteric Virus Group, Murdoch Childrens Research Institute, Royal Children’s Hospital, Parkville, and Department of Microbiology, La Trobe University, Bundoora, Victoria, Australia

Max Ciarlet Clinical Research and Development, Novartis Vaccines and Diagnostics, Cambridge, MA, USA; Clinical Research and Development, Novartis Vaccines and Diagnostics, Cambridge, MA, USA

Ulrich Desselberger Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK; Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK

Marc Van Ranst Laboratory of Clinical and Epidemiological Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium; Laboratory of Clinical and Epidemiological Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium

Abstract

Two human group A rotavirus (RVA) vaccines are available and highly effective in preventing severe gastroenteritis caused by all commonly circulating human RVA genotypes. The effect of universal mass vaccination on the RVA genotype distribution is discussed based on the knowledge of complete RVA genotype constellations, data from clinical efficacy trials and effectiveness studies, and genotype surveillance data from countries with universal mass vaccination programs. The theoretically predicted relative enrichment of RVA strains with the G2P[4] DS-1-like genotype constellation in regions with high coverage by Rotarix^® (GlaxoSmithKline Biologicals, Rixensart, Belgium) seems to become apparent. A G3P[8] genotype increase, which was noted in several regions with a high coverage of RotaTeq^® (Merck and Co., Inc., NJ, USA), is more difficult to explain based on the theoretical considerations.

Keywords::

Financial & competing interests disclosure

J Matthijnssens was supported by a ‘Fonds voor Wetenschappelijk Onderzoek’ postdoctoral fellowship. CD Kirkwood was supported by a National Health and Medical Research Council CDA fellowship (609347). J Matthijnssens and M Van Ranst were investigators in a postmarketing effectiveness study conducted in Belgium and sponsored by GlaxoSmithKline Biologicals. C Kirkwood is Director of the Australian Rotavirus Surveillance Program, which is supported by research grants from GlaxoSmithKline Biologicals and CSL. M Ciarlet was employed at Merck and Co., Inc. when the pivotal rotavirus efficacy and postmarketing effectiveness studies were performed, and owned stock in the company. U Desselberger was a member of the GSK-supported PROTECT group, which was dissolved in 2010. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Group A rotavirus universal mass vaccination: how and to what extent will selective pressure influence prevalence of rotavirus genotypes?

Information for

Open access

Opportunities

Help and information

Group A rotavirus universal mass vaccination: how and to what extent will selective pressure influence prevalence of rotavirus genotypes?

Abstract

Financial & competing interests disclosure

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature